A Novel Approach for Dermal Application of Pranoprofen-Loaded Lipid Nanoparticles for the Treatment of Post-Tattoo Inflammatory Reactions

Recently, the number of people acquiring tattoos has increased, with tattoos gaining significant popularity in people between 20 and 40 years old. Inflammation is a common reaction associated with tattooing. The purpose of this study was to evaluate a nanostructured lipid carrier loading pranoprofen...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2024-05, Vol.16 (5), p.643
Main Authors: De Grau-Bassal, Guillermo, Mallandrich, Mireia, Sosa, Lilian, Espinoza, Lupe, Calpena, Ana Cristina, Bozal-de Febrer, Núria, Rodríguez-Lagunas, María J, Garduño-Ramírez, María L, Rincón, María
Format: Article
Language:English
Subjects:
anti-inflammatory
Arthritis
Chemicals
drug delivery system
Drug delivery systems
Drugs
Homogenization
Hydration
Inflammation
Lipids
Mammaplasty
nanostructured lipid carriers (NLC)
Particle size
Polyethylene glycol
pranoprofen (PRA)
Psoriasis
Radiation
Skin
Tattoos
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, the number of people acquiring tattoos has increased, with tattoos gaining significant popularity in people between 20 and 40 years old. Inflammation is a common reaction associated with tattooing. The purpose of this study was to evaluate a nanostructured lipid carrier loading pranoprofen (PRA-NLC) as a tattoo aftercare formulation to reduce the inflammation associated with tattooing. In this context, the in vitro drug release and the ex vivo permeation-through-human-skin tests using Franz cells were appraised. The tolerance of our formulation on the skin was evaluated by studying the skin's biomechanical properties. In addition, an in vivo anti-inflammatory study was conducted on mice skin to evaluate the efficacy of the formulation applied topically after tattooing the animals. PRA-NLC showed a sustained release up to 72 h, and the amount of pranoprofen retained in the skin was found to be 33.48 µg/g/cm . The formulation proved to be well tolerated; it increased stratum corneum hydration, and no signs of skin irritation were observed. Furthermore, it was demonstrated to be non-cytotoxic since the cell viability was greater than 80%. Based on these results, we concluded that PRA-NLC represents a suitable drug delivery carrier for the transdermal delivery of pranoprofen to alleviate the local skin inflammation associated with tattooing.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics16050643